To Create The Pain Relief Parity Act; And To Require Pain Relief Parity In The Arkansas Medicaid Program.
Summary
HB1186 creates the “Pain Relief Parity Act” and directs the Arkansas Department of Human Services to treat certain non-opioid pain medications no less favorably than opioid or narcotic pain drugs in the Arkansas Medicaid Program. The bill applies to the Medicaid formulary and preferred drug list, requiring that a non-opioid drug approved by the U.S. Food and Drug Administration and without a therapeutic equivalent for pain treatment not be disadvantaged or discouraged in coverage compared with opioids or narcotics.
Specifically, the bill prohibits Medicaid from making such non-opioid pain drugs non-preferred if an opioid or narcotic is preferred, and it also bars more restrictive utilization controls for non-opioids than for comparable opioid or narcotic drugs. In practical terms, the measure is intended to improve access to certain non-opioid pain treatments and limit coverage practices that could steer patients toward opioid-based options.
Impact
The bill amends Arkansas Code Title 20, Chapter 77, Subchapter 4 by adding a new section on Medicaid pain relief parity. It changes how the Department of Human Services may structure the Medicaid formulary, preferred drug list, prior authorization, and step therapy rules for pain medications, but only for non-opioid drugs that are FDA-approved and have no therapeutic equivalent for pain management. The law affects Medicaid beneficiaries, prescribers, pharmacies, and drug manufacturers by constraining coverage decisions that could otherwise favor opioids over certain non-opioid alternatives.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House and Senate by unanimous or near-unanimous votes, including 95-0 in the House, 35-0 in the Senate on third reading, and 90-0 on concurrence with a Senate amendment. The vote history suggests the measure was viewed favorably as a patient-access and pain-management policy rather than a controversial change.
Contention
No committee debate or recorded opposition is provided, and the vote totals indicate no significant floor resistance. Any potential point of contention would likely center on Medicaid formulary management and whether the state should limit DHS discretion in designing preferred drug lists and utilization controls. The bill’s supporters appear to prioritize access to non-opioid pain relief and reducing reliance on opioids, while any critics would likely be concerned about cost, administrative flexibility, or the impact on utilization management, though none are reflected in the available record.